Improving care for patients with Clostridioides difficile infection (CDI)

Challenges and opportunities for diagnosis, treatment and management in Australia

Lucy Hocking, Mark Wilcox, Nicola Petrosillo, Paul Griffin, Theodore Steiner, Gail Attara, Joel Doré, Mark Cabling, Stephanie Stockwell, Robert J. Romanelli, et al.

Data VizPublished Sep 30, 2024

Cover: Improving care for patients with <em>Clostridioides difficile</em> infection (CDI)
Download PDF
Additional Downloads

Includes Translations

Clostridioides difficile (C. Difficile) is a bacterium commonly restricted to low numbers in the human gut without harm. However, imbalance of the gut environment — often in response to antibiotic use or after gastrointestinal surgery — leads to its overgrowth and production of harmful toxins, known as C. Difficile Infection (CDI). The objective of this research was to better understand the key challenges in the clinical care pathway for CDI to inform future clinical practice and policy.

Topics

Document Details

  • Copyright: Ferring Pharmaceuticals
  • Publisher: RAND Corporation
  • Availability: Web-Only
  • Year: 2024
  • Pages: 1
  • DOI: https://doi.org/10.7249/IGA3265-3
  • Document Number: IG-A3265-3

Citation

RAND Style Manual
Hocking, Lucy, Mark Wilcox, Nicola Petrosillo, Paul Griffin, Theodore Steiner, Gail Attara, Joel Doré, Mark Cabling, Stephanie Stockwell, Robert J. Romanelli, and Sonja Marjanovic, Improving care for patients with Clostridioides difficile infection (CDI): Challenges and opportunities for diagnosis, treatment and management in Australia, RAND Corporation, IG-A3265-3, 2024. As of October 6, 2024: https://www.rand.org/pubs/infographics/IGA3265-3.html
Chicago Manual of Style
Hocking, Lucy, Mark Wilcox, Nicola Petrosillo, Paul Griffin, Theodore Steiner, Gail Attara, Joel Doré, Mark Cabling, Stephanie Stockwell, Robert J. Romanelli, and Sonja Marjanovic, Improving care for patients with Clostridioides difficile infection (CDI): Challenges and opportunities for diagnosis, treatment and management in Australia. Santa Monica, CA: RAND Corporation, 2024. https://www.rand.org/pubs/infographics/IGA3265-3.html.
BibTeX RIS

Research conducted by

This study was funded by Ferring Pharmaceuticals and was independently conducted by RAND Europe.

This publication is part of the RAND infographic series. RAND infographics are design-focused, visual representations of data and information based on a published, peer-reviewed product or a body of published work.

All rights reserved. Only one copy of this document may be retained for personal non-commercial use. Otherwise no part of this document may be reproduced in any form by any electronic or mechanical means (including photocopying, recording, or information storage and retrieval) without permission in writing from Ferring Pharmaceuticals.

RAND is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.